A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activityMiriam Kim(Washington University in St. Louis), John F. DiPersio(Washington University in St. Louis)Nature CommunicationsJune 13, 202210.1038/s41467-022-30860-0Cited by 95SaveCiteExport RISWatch citationsRelated PapersCD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy|JCI Insight|2021|40